在神经退行性疾病中,通过agmatine对线粒体动态的治疗调节
Dhanshree Nibrad1, Amit Shiwal1, Manasi Tadas1
1Division of Neuroscience, Department of Pharmacology, Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur, (M.S.) 441 002, India.
Neuroscience
|January 31, 2025
概括
阿格马通过维护线粒体健康来保护大脑细胞的潜力,为阿尔茨海默氏症和帕金森氏症等神经退行性疾病提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 线粒体功能障碍是神经退行性疾病发病的核心.
- 氧化应激,能量产生受损和失调节有助于神经元损失.
- 阿格马丁是一种内源性聚胺,表现出神经保护作用.
研究的目的:
- 探索阿格马丁在神经退行过程中维护线粒体功能的作用.
- 为了研究与线粒体相关的阿格马丁神经保护机制.
- 评估阿格马丁作为神经退行性疾病的潜在治疗剂.
主要方法:
- 关于阿格马丁和线粒体平衡的最近研究的综述.
- 对阿格马丁对线粒体动力学 (融合/裂变) 的影响的分析.
- 检查阿格马丁对线粒体透性过渡孔 (mPTP) 的调节.
主要成果:
- 阿格马丁调节线粒体动力学,平衡融合和裂变.
- 阿格马丁调节mPTP的开放,防止过载和线粒体损伤.
- 阿格马丁具有抗炎,抗氧化和抗位性质.
结论:
- 阿格马丁维护线粒体平衡,对神经保护至关重要.
- 阿格马丁为神经退行性疾病提供了一个有前途的治疗策略.
- 需要进一步的研究来优化阿格马丁的输送,剂量和目标.
更多相关视频
11:47Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
Published on: January 22, 2017
10.5K
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
419
相关概念视频
Electron Transport Chain: Complex I and II
10.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.6K
Mitochondrial Membranes
7.5K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
7.5K
Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
ATP Synthase: Mechanism
13.8K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
13.8K
Mitochondria
9.9K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
9.9K
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
